Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000250186 is a long non-coding RNA, annotated as "novel transcript, antisense to PHB". This lncRNA is transcribed from the strand opposite to the PHB gene but does not encode a protein[2]. Natural antisense transcripts such as this can modulate gene expression or RNA stability through various mechanisms, such as altering chromatin state, modulating mRNA processing, or masking miRNA binding sites—as observed in the general class of antisense lncRNAs[1][4]. The specific biological or disease relevance of ENSG00000250186 has not been characterized; its annotation is based on transcriptomic data, and there is no evidence of therapeutic targeting or clinical application. Essentially, ENSG00000250186 is not a receptor, enzyme, drug target, or classic disease gene. It is a non-coding RNA with the potential for regulatory functions through antisense mechanisms, though no direct experimental data exist for its functional or therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to PHB.